15-Year watch: tracking patients after experimental cancer cell therapy
NCT ID NCT06906380
Summary
This study will monitor patients for 15 years after they received an experimental CAR-T cell therapy for relapsed or hard-to-treat blood cancers like acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS). The main goal is to understand the long-term safety of the treatment by tracking any health problems that might occur. No new treatment is given during this follow-up period.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ACUTE MYELOID LEUKEMIA, IN RELAPSE are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
MD Anderson Cancer Center
Houston, Texas, 77030, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Novant Health Cancer Institute
Charlotte, North Carolina, 28204, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Novant Health Cancer Institute
Winston-Salem, North Carolina, 27201, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.